TAK
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
Best Pharmaceutical Stocks 2026 →
TAK Stock Analysis: Buy, Sell, or Hold?
$21.12
+0.28 (+1.34%)
▲
5d:
-0.33%
30d:
+11.1%
90d:
+19.8%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (27%)
Quality Score
35/100
Position
EXTENDED
30-Day Fair Range
$18.90 – $20.94
Position: EXTENDED
Forward P/E & Valuation
0.2x
FAIR
vs 0.2x historical avg
Wall Street Target
$22.77
+7.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$20.57 / $21.73
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: TAK shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When TAK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.99
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$22.97
8.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TAK is currently trading at $21.12, which is considered extended relative to its 30-day fair value range of $18.90 to $20.94. The stock's valuation (Forward PE: 0.2) is in line with its historical norms (0.2). At these levels, the market is pricing in 6.5% annual earnings growth.
Technical Outlook: Technically, TAK is in a strong uptrend. The price is currently testing key support at $20.57. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TAK scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TAK is in a strong uptrend. The price is currently testing key support at $20.57. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TAK scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$18.90 -
$20.94
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
27.1%
Trading Range & Key Levels
30-Day Trading Range
$18.90 -
$20.94
Current vs Trading Range
EXTENDED
Support Level
$20.57
Resistance Level
$21.73
Current Trend
Strong Uptrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($22.77)
- BULLISH: Expecting earnings turnaround to 6.5% growth with 6.7% revenue growth
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
0.22
Wall Street Target
$22.77
(+7.8%)
Revenue Growth (YoY)
6.7%
Earnings Growth (YoY)
-9.8%
Profit Margin
0.9%
Valuation Premium vs History
+6.5% premium
PE vs Historical
0.2 vs 0.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.5%
(market-implied from PE analysis)
1-Year Target
$22.49
(+7%)
2-Year Target
$23.95
(+13%)
3-Year Target
$25.51
(+21%)
3-Yr Target (if PE normalizes)
(PE: 0→0)
PE COMPRESSION
$22.95
(+9%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 93.0%)
$6366.41
(+30044%)
Base:
(SPY PE: 0.2, Growth: 93.0%)
$71.28
(+238%)
Bear:
(PE: 0.2, Growth: 93.0%)
$60.59
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (0x PE) as earnings recover.
Forward PE: 12.77 | Forward EPS (Implied): $1.65
Bull Case
$25.50
(+21%)
Analyst growth 15.0%, PE expands to 13.4
Base Case
$21.12
(0%)
Market implied 0.0%, PE stable at 12.8
Bear Case
$16.16
(-24%)
Severe decline -15.0%, PE contracts to 11.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share TAK Analysis
Share this live TAK analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (TAK)
Bullish
1 Retail Mentions
Reddit / WSB Comments
1
Bullish
Last Tracked
Oct 10, 2023
Daily AI digest
AI Retail Discussion Summary:
Reddit & WallStreetBets discussions on TAK are bullish (sentiment score +0.24) across 1 tracked comments.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 8:56 PM ET
Data refreshes hourly during market hours. Next update: 9:56 PM
Data refreshes hourly during market hours. Next update: 9:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TAK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 41 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 60 BUY |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
15 analysts |
$49 | 36 SELL |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 51 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive TAK Research Pages
